Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma

Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer

(2018) Christopher J. Halbrook et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004

(2018) Shu-ta Wu et al.   PLoS One

Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine

(2018) Manendra Babu Lankadasari et al.   Theranostics

Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition

(2018) Hussein Sultan et al.   Cancer Immunology Research

Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy

(2018) Neus Martinez-Bosch et al.   Cancers

The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients

(2017) Matteo Piciucchi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

(2017) Akash Patnaik et al.   Cancer Discovery

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy

(2017) Masaki Terabe et al.   OncoImmunology

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment

(2017) Michael R. Cassidy et al.   EBioMedicine

CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy

(2016) Katelyn T. Byrne et al.   JOURNAL OF IMMUNOLOGY

A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis

(2016) R Zhou et al.   ONCOGENE

Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors

(2016) Laura Jeffords Moore et al.   Translational Oncology

Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base

(2016) Katelin A. Mirkin et al.   International Journal of Surgery

Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment

(2016) Bin Zhang et al.   Oncotarget

A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells

(2016) Makiko Yamashita et al.   Scientific Reports

Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes

(2016) L. E. Klevorn et al.   Cancer Immunology Research

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

Myeloperoxidase Inhibitors as Potential Drugs

(2015) Tamara Lazarevic-Pasti et al.   CURRENT DRUG METABOLISM

IL-6 as a keystone cytokine in health and disease

(2015) Christopher A Hunter et al.   NATURE IMMUNOLOGY

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

(2015) Ignacio Garrido-Laguna et al.   Nature Reviews Clinical Oncology

NK cells require IL-28R for optimal in vivo activity

(2015) Fernando Souza-Fonseca-Guimaraes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction

(2015) Masahiro Tanemura   WORLD JOURNAL OF GASTROENTEROLOGY

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma

(2014) T. L. Tinder et al.   JOURNAL OF IMMUNOLOGY

Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition

(2014) P. Mukherjee et al.   JOURNAL OF IMMUNOLOGY

Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy

(2014) Amedeo Amedei et al.   Human Vaccines & Immunotherapeutics

Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo

(2013) Li Ye et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity

(2013) B. Kwong et al.   CANCER RESEARCH

Perioperative Influenza Vaccination Reduces Postoperative Metastatic Disease by Reversing Surgery-Induced Dysfunction in Natural Killer Cells

(2013) L.-H. Tai et al.   CLINICAL CANCER RESEARCH

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

(2013) Caroline B. Madsen et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

IFN- -rich environment programs dendritic cells toward silencing of cytotoxic immune responses

(2013) U. Svajger et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer

(2013) Jennifer M. Curry et al.   JOURNAL OF SURGICAL ONCOLOGY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity

(2012) Jorge Schettini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer

(2012) Stephanie K. Bunt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Utility of Immunohistochemistry for the Identification of Hematopoietic and Lymphoid Cells in Normal Tissues and Interpretation of Proliferative and Inflammatory Lesions of Mice and Rats

(2012) Jerold E. Rehg et al.   TOXICOLOGIC PATHOLOGY

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung

(2011) Zvi Granot et al.   CANCER CELL

Pancreatic Ductal Adenocarcinoma Mice Lacking Mucin 1 Have a Profound Defect in Tumor Growth and Metastasis

(2011) D. M. Besmer et al.   CANCER RESEARCH

T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab

(2011) B. E. Wahlin et al.   CLINICAL CANCER RESEARCH

Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages

(2011) Q. Zhao et al.   JOURNAL OF IMMUNOLOGY

Natural and Induced Humoral Responses to MUC1

(2011) Silvia Von Mensdorff-Pouilly et al.   Cancers

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas

(2010) Xavier Poiré et al.   LEUKEMIA & LYMPHOMA

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

(2008) Aruna Mani et al.   BREAST CANCER RESEARCH AND TREATMENT